NICE says yes to eye condition treatment in final guidance

The National Institute for Health and Clinical Excellence (NICE) has published final guidance recommending ocriplasmin (Jetrea, ThromboGenics) as an option for treating some people with the rare eye condition, vitreomacular traction.   Vitreomacular traction occurs when the vitreous, the gel-like substance in the eye, pulls abnormally on the retina, the light-sensitive layer of tissue at the back of the inner eye, which is responsible for processing visual images. The pulling of the gel disturbs the retina, causing swelling and distorted vision, and sometimes a hole in the macular area. It can occur as a result of ageing.   NICE has